Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Department of Internal Medicine, The Catholic University of Korea, Eunpyeong St Mary's Hospital, Seoul, South Korea.
Gastrointest Endosc. 2023 Apr;97(4):741-751.e1. doi: 10.1016/j.gie.2022.11.004. Epub 2022 Nov 16.
Treatment strategies for small pancreatic neuroendocrine tumors (PNETs) <2 cm in size are still under debate. The feasibility and safety of EUS-guided ethanol ablation (EUS-EA) have been demonstrated. However, sample sizes in previous studies were small with no comparative studies on surgery. Therefore, we aimed to compare the safety and long-term outcomes of EUS-EA with those of surgery for the management of nonfunctioning small PNETs.
We retrospectively reviewed patients with PNETs who were managed by EUS-EA (from 2011 to 2018) and surgery (from 2000 to 2018) at Asan Medical Center. Propensity score matching (PSM) was performed to increase comparability. The primary outcome was early and late major adverse events (Clavien-Dindo grade ≥III) after treatment. Secondary outcomes were 10-year overall (OS) and disease-specific survival (DSS) rates, length of hospital stay, and development of endocrine pancreatic insufficiency.
Of all patients, 97 and 188 patients were included in the EUS-EA and surgery groups, respectively. PSM created 89 matched pairs. EUS-EA was associated with a significantly lower rate of early major adverse events (0% vs 11.2%, P = .003). Late major adverse events occurred more frequently after surgery, with no significant difference between groups (3.4% vs 10.1%, P = .07). Both treatment modalities showed comparable 10-year OS and DSS rates. The length of hospital stay was significantly shorter in the EUS-EA group (4 days vs 14.1 days, P < .001), and endocrine pancreatic insufficiency was less common after EUS-EA than after surgery (33.3% vs 48.6%, P = .121).
EUS-EA had fewer adverse events and a shorter hospital stay with similar OS and DSS rates compared with surgery, suggesting that EUS-EA may be a preferred alternative to surgical resection in selected patients with nonfunctioning small PNETs.
对于直径<2cm 的胰腺神经内分泌肿瘤(PNETs)的治疗策略仍存在争议。EUS 引导下乙醇消融术(EUS-EA)的可行性和安全性已经得到证实。然而,之前的研究样本量较小,且没有关于手术的对照研究。因此,我们旨在比较 EUS-EA 与手术治疗无功能性小 PNETs 的安全性和长期结果。
我们回顾性分析了 2011 年至 2018 年在 Asan 医疗中心接受 EUS-EA 治疗(EUS-EA 组)和 2000 年至 2018 年接受手术治疗(手术组)的 PNETs 患者。采用倾向评分匹配(PSM)提高可比性。主要结局是治疗后早期和晚期主要不良事件(Clavien-Dindo 分级≥III)。次要结局是 10 年总生存率(OS)和疾病特异性生存率(DSS)、住院时间和内分泌胰腺功能不全的发展。
所有患者中,EUS-EA 组和手术组分别纳入 97 例和 188 例患者。PSM 共创建 89 对匹配。EUS-EA 组早期主要不良事件发生率显著较低(0% vs 11.2%,P=0.003)。手术组晚期主要不良事件发生率较高,但组间无显著差异(3.4% vs 10.1%,P=0.07)。两种治疗方法的 10 年 OS 和 DSS 率相当。EUS-EA 组的住院时间明显更短(4 天 vs 14.1 天,P<0.001),EUS-EA 后发生内分泌胰腺功能不全的比例低于手术组(33.3% vs 48.6%,P=0.121)。
EUS-EA 治疗直径<2cm 的无功能性胰腺神经内分泌肿瘤具有更少的不良事件和较短的住院时间,与手术相比,其 10 年 OS 和 DSS 率相似,提示 EUS-EA 可能是无功能性小 PNETs 患者的一种替代手术切除的首选方法。